Davita Inc (DVA) Receives $82.50 Consensus PT from Analysts
Davita Inc (NYSE:DVA) has earned a consensus recommendation of “Hold” from the twelve brokerages that are covering the firm, Marketbeat.com reports. Seven equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $85.80.
DVA has been the subject of several analyst reports. Zacks Investment Research lowered Davita from a “buy” rating to a “hold” rating in a research note on Tuesday, October 23rd. ValuEngine lowered Davita from a “buy” rating to a “hold” rating in a research note on Wednesday, October 17th. TheStreet lowered Davita from a “b-” rating to a “c+” rating in a research note on Thursday. JPMorgan Chase & Co. upgraded Davita from an “underweight” rating to a “neutral” rating in a research note on Thursday, September 13th. Finally, Raymond James lowered Davita from a “strong-buy” rating to a “market perform” rating in a research note on Thursday.
Hedge funds have recently modified their holdings of the business. Vigilant Capital Management LLC increased its stake in Davita by 250.0% in the 2nd quarter. Vigilant Capital Management LLC now owns 2,100 shares of the company’s stock worth $146,000 after buying an additional 1,500 shares in the last quarter. Atlas Capital Advisors LLC boosted its holdings in shares of Davita by 247.9% during the 3rd quarter. Atlas Capital Advisors LLC now owns 2,592 shares of the company’s stock valued at $188,000 after purchasing an additional 1,847 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. bought a new position in shares of Davita during the 2nd quarter valued at about $206,000. Green Square Capital LLC bought a new position in shares of Davita during the 2nd quarter valued at about $208,000. Finally, IFG Advisory LLC bought a new position in shares of Davita during the 2nd quarter valued at about $213,000. Institutional investors and hedge funds own 87.36% of the company’s stock.
Davita (NYSE:DVA) last posted its quarterly earnings data on Wednesday, November 7th. The company reported $0.56 EPS for the quarter, missing the consensus estimate of $0.89 by ($0.33). The company had revenue of $2.85 billion during the quarter, compared to analysts’ expectations of $2.93 billion. Davita had a return on equity of 13.37% and a net margin of 5.39%. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter last year, the company earned $0.81 earnings per share. On average, equities research analysts expect that Davita will post 4 earnings per share for the current fiscal year.
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Featured Article: Fundamental Analysis – How It Helps Investors
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.